secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2025-03-18T23:59:59+00:00
Accession:  0000950170-25-041187
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Trevi Therapeutics Reports Q4 and Full Year 2024 Financial Results and Provides Positive Clinical Updates
--------------------------------------------------------------------------------

- Announced positive topline data from Phase 2a RIVER trial in refractory chronic cough, meeting primary endpoint with 57% placebo-adjusted reduction in 24-hour cough frequency.
- Completed enrollment in Phase 2b CORAL trial in IPF patients with chronic cough, topline data expected Q2 2025.
- Sample size re-estimation for CORAL trial reaffirmed original sample size of 160 patients.
- Ended 2024 with $107.6 million cash, expected runway into H2 2026.
- Net loss for 2024 was $47.9 million, compared to $29.1 million in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000095017025041187/0000950170-25-041187-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000095017025041187/trvi-20250318.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-041187

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer